Bolt Biotherapeutics, Inc. (BOLT) is a clinical-stage immuno-oncology company pioneering the development of tumor-targeted therapies. The core platform of Bolt Biotherapeutics is its Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC). Boltbody™ ISACs are designed to harness the power of the immune system by targeting tumor cells and creating an inflammatory tumor microenvironment to ignite the immune system and enable it to destroy and attack cancerous cells.
The company was founded in 2015 by Dr. Ed Engleman, a renowned scientist and inventor of the first FDA-approved therapeutic cancer vaccine, Provenge. The company is based in Redwood City, California, and it’s committed to discovering and developing innovative, first-in-class therapies which can improve the lives of patients suffering from cancer all around the world.
Bolt Biotherapeutics' lead program, BDC-1001, is a HER2-targeted Boltbody™ ISAC, which is currently in a Phase 1/2 clinical trial for patients with HER2-expressing solid tumors. This adventure represents a promising advance in the field of immunotherapy – a branch of medicine that uses the body's own immune system to help fight cancer – a category that includes potentially revolutionary treatments like CAR-T cell therapy.
In addition to BDC-1001, Bolt Biotherapeutics is also progressing multiple Boltbody™ ISAC programs aimed at cellular targets expressed across a wide range of solid tumors. The brilliance in the Boltbody™ ISAC approach lies in its ability to engage the immune system's innate response by converting cold tumors to hot, thereby triggering a powerful, systemic immune response.
This company is powered by a team of seasoned drug developers and scientists who are passionate about leveraging immunology principles to develop the next wave of cancer therapies. They strive for a culture of creativity, intellectual curiosity, and a focus on improving patient outcomes.
In summary, Bolt Biotherapeutics, Inc. is a cutting-edge life sciences company, committed to unlocking the power of the immune system to fight cancer. The company's innovative Boltbody™ ISAC platform paves the way for next-generation treatments, looking to revolutionize cancer therapies and improve patient survival rates.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Coastlands Capital LP has reported the acquisition of 50,000 common shares of Bolt Biotherapeutics (NASDAQ:BOLT) on November 9, 2026. The shares were purchased at a weighted average price of $6.38 each, increasing Coastlands Capital LP's indirect beneficial ownership to 462,416 shares. This transaction further solidifies Coastlands Capital LP's position as a 10% owner of Bolt Biotherapeutics.
Bolt Biotherapeutics, Inc. (Nasdaq: BOLT) announced its participation in two upcoming investor conferences: the Stifel 2026 Healthcare Conference and the Jefferies Global Healthcare Conference. Sheila Gujrathi, M.D., Chief Strategy Officer, will present company updates, focusing on the pipeline acquired from Prana Therapies, including the lead program PRA-216. The company recently acquired Prana Therapies in a reverse merger and secured $120 million in private placement financing.
Bolt Biotherapeutics (Nasdaq: BOLT) announced its participation in two upcoming investor conferences. Sheila Gujrathi, M.D., Chief Strategy Officer, will present at the Stifel 2026 Healthcare Conference and attend the Jefferies Global Healthcare Conference in London. The company's primary focus, following its acquisition of Prana Therapies, is advancing Prana's pipeline of half-life-extended multispecific antibodies, including PRA-216, which is in Phase 2 development for inflammatory diseases.
Monteverde & Associates PC, a class action law firm, has announced an investigation into Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) following its merger with Prana Therapies, Inc. The firm, recognized for recovering millions for shareholders, encourages Bolt stockholders to contact them to determine if the merger is a fair deal. They emphasize their track record in class action litigation and invite shareholders with concerns to seek a free consultation.
Bolt Biotherapeutics has acquired Prana Therapies through a reverse merger and secured $120 million in private placement funding, with a potential additional $60 million from warrants, to advance Prana's multispecific antibody pipeline. The primary focus will be on PRA-216, a drug candidate in Phase 2 development for asthma, COPD, and atopic dermatitis, with initial patient data expected in Q2 2027. This financing is anticipated to fund operations into 2028 and through several key clinical milestones.
Bolt Biotherapeutics (Nasdaq: BOLT) experienced a significant surge, trading up more than 63% to a 52-week high, following its acquisition of Prana Therapies in a reverse merger and a $120 million private placement. This financing is expected to fund operations into 2028 and advance Prana's pipeline, including the lead program PRA-216, a bispecific antibody in Phase 2 development for inflammatory diseases. The acquisition aims to leverage Prana's INSPIRE platform to develop next-generation multispecific antibodies.